<DOC>
	<DOCNO>NCT00322413</DOCNO>
	<brief_summary>The two epoetins , Epoetin alfa , well establish drug treat renal anemia Epoetin Omega , differs Epoetin alfa sugar moiety molecule compare regard efficacy safety treat end stage renal disease anemia . Study hypothesis Epoetin Omega non-inferior Epoetin alfa correct renal anemia dialysis patient . A 12-weeks randomized comparative efficacy study perform include 77 end stage renal disease patient ( epoetin omega : n=39 , epoetin alfa : n=38 ) . In intent-to-treat analysis , average weekly difference hemoglobin versus baseline value high omega-treated patient : 1.94+-0.81 vs. 1.23+-0.62 g/dl . The unadjusted adjusted omega-alfa difference 0.71 g/dl ( 95 % CI 0.38 1.04 ; p &lt; 0.001 ) 0.78 g/dl ( 0.49 1.08 ; p &lt; 0.001 ) , respectively . Average weekly epoetin dose low omega group : 87+-25 vs. 108+-21 IU/kg . The unadjusted adjusted omega-alfa difference -21IU/kg ( -32 -11 ; p &lt; 0.001 ) -24IU/kg ( -35 -13 ; p &lt; 0.001 ) , respectively . Epoetins comparably well tolerate . In dialysis patient , subcutaneous epoetin omega apparently provide great anti-anemic effect per administer dose ( IU ) epoetin alfa .</brief_summary>
	<brief_title>Comparison Epoetin Alfa Epoetin Omega Anemic Dialysis Patients : Results Efficacy Trial</brief_title>
	<detailed_description>The two epoetins , Epoetin alfa , well establish drug treat renal anemia Epoetin Omega , differs Epoetin alfa sugar moiety molecule compare regard efficacy safety treat end stage renal disease anemia . Study hypothesis Epoetin Omega non-inferior Epoetin alfa correct renal anemia dialysis patient . A 12-weeks randomized comparative efficacy study perform include 77 end stage renal disease patient ( epoetin omega : n=39 , epoetin alfa : n=38 ) . All patient anemic ( Hemoglobin &lt; 90 g/L ) , treat regular hemodialysis without sign bleed , hemolysis , inflammation history major surgery.Treatment start 50 IU/kg body weight subcutaneously per week thereafter adjust accord hemoglobin response . In intent-to-treat analysis , average weekly difference hemoglobin versus baseline value high omega-treated patient : 1.94+-0.81 vs. 1.23+-0.62 g/dl . The unadjusted adjusted omega-alfa difference 0.71 g/dl ( 95 % CI 0.38 1.04 ; p &lt; 0.001 ) 0.78 g/dl ( 0.49 1.08 ; p &lt; 0.001 ) , respectively . Average weekly epoetin dose low omega group : 87+-25 vs. 108+-21 IU/kg . The unadjusted adjusted omega-alfa difference -21IU/kg ( -32 -11 ; p &lt; 0.001 ) -24IU/kg ( -35 -13 ; p &lt; 0.001 ) , respectively . Epoetins comparably well tolerate . In dialysis patient , subcutaneous epoetin omega apparently provide great anti-anemic effect per administer dose ( IU ) epoetin alfa .</detailed_description>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>End stage renal disease Regular dialysis treatment Renal anemia ( hemoglobin &lt; 9.0 g/dl ) Age &gt; 18 year Adequate iron store ( TIBC saturation &gt; 20 % , ferritin &gt; 200 ) Signs bleed Major surgery previous 60 day Hemolysis Other cause anemia Cancer Inflammatory disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>Epoetin alfa</keyword>
	<keyword>Epoetin omega</keyword>
	<keyword>Comparative efficacy trial</keyword>
	<keyword>Renal anemia</keyword>
</DOC>